Primary	B:C0206695
neuroendocrine	I:C0206695
carcinoma	I:C0206695
of	O
the	O
breast	O
A	O
single	O
Center	I:C0596545
experience	I:C0596545
and	O
review	O
of	I:C0282441
the	I:C0282441
literature	I:C0282441
Neuroendocrine	O
carcinoma	I:C0206695
of	O
the	O
breast	O
is	O
an	O
extremely	O
rare	O
tumor	O
.	O

Primary	O
neuroendocrine	I:C0206695
carcinoma	I:C0206695
of	O
the	O
breast	B:C0006141
A	O
single	O
Center	I:C0596545
experience	I:C0596545
and	O
review	O
of	I:C0282441
the	I:C0282441
literature	I:C0282441
Neuroendocrine	O
carcinoma	I:C0206695
of	O
the	O
breast	O
is	O
an	O
extremely	O
rare	O
tumor	O
.	O

Primary	O
neuroendocrine	I:C0206695
carcinoma	I:C0206695
of	O
the	O
breast	O
A	O
single	B:C0596545
Center	I:C0596545
experience	I:C0596545
and	O
review	O
of	I:C0282441
the	I:C0282441
literature	I:C0282441
Neuroendocrine	O
carcinoma	I:C0206695
of	O
the	O
breast	O
is	O
an	O
extremely	O
rare	O
tumor	O
.	O

Primary	O
neuroendocrine	I:C0206695
carcinoma	I:C0206695
of	O
the	O
breast	O
A	O
single	O
Center	I:C0596545
experience	I:C0596545
and	O
review	B:C0282441
of	I:C0282441
the	I:C0282441
literature	I:C0282441
Neuroendocrine	O
carcinoma	I:C0206695
of	O
the	O
breast	O
is	O
an	O
extremely	O
rare	O
tumor	O
.	O

Primary	O
neuroendocrine	I:C0206695
carcinoma	I:C0206695
of	O
the	O
breast	O
A	O
single	O
Center	I:C0596545
experience	I:C0596545
and	O
review	O
of	I:C0282441
the	I:C0282441
literature	I:C0282441
Neuroendocrine	B:C0206695
carcinoma	I:C0206695
of	O
the	O
breast	O
is	O
an	O
extremely	O
rare	O
tumor	O
.	O

Primary	O
neuroendocrine	I:C0206695
carcinoma	I:C0206695
of	O
the	O
breast	O
A	O
single	O
Center	I:C0596545
experience	I:C0596545
and	O
review	O
of	I:C0282441
the	I:C0282441
literature	I:C0282441
Neuroendocrine	O
carcinoma	I:C0206695
of	O
the	O
breast	B:C0006141
is	O
an	O
extremely	O
rare	O
tumor	O
.	O

Primary	O
neuroendocrine	I:C0206695
carcinoma	I:C0206695
of	O
the	O
breast	O
A	O
single	O
Center	I:C0596545
experience	I:C0596545
and	O
review	O
of	I:C0282441
the	I:C0282441
literature	I:C0282441
Neuroendocrine	O
carcinoma	I:C0206695
of	O
the	O
breast	O
is	O
an	O
extremely	O
rare	O
tumor	B:C0027651
.	O

A	O
standard	O
treatment	B:C0087111
has	O
yet	O
to	O
be	O
established	O
because	O
only	O
a	O
few	O
cases	O
have	O
been	O
reported	O
in	O
literature	O
.	O

A	O
standard	O
treatment	O
has	O
yet	O
to	O
be	O
established	O
because	O
only	O
a	O
few	O
cases	O
have	O
been	O
reported	O
in	O
literature	B:C0023866
.	O

The	O
authors	B:C3812881
report	O
five	O
cases	O
observed	O
from	O
January	O
2007	O
to	O
December	O
2014	O
and	O
a	O
review	O
of	I:C0282441
literature	I:C0282441
.	O

The	O
authors	O
report	O
five	O
cases	O
observed	O
from	O
January	O
2007	O
to	O
December	O
2014	O
and	O
a	O
review	B:C0282441
of	I:C0282441
literature	I:C0282441
.	O

Four	O
patients	O
underwent	O
quadrantectomy	B:C0337354
and	O
in	O
two	O
cases	O
axillary	O
nodal	I:C0024203
dissection	I:C0024203
and	O
only	O
one	O
to	O
mastectomy	O
with	O
axillary	O
nodal	I:C0024203
dissection	I:C0024203
.	O

Four	O
patients	O
underwent	O
quadrantectomy	O
and	O
in	O
two	O
cases	O
axillary	B:C0024203
nodal	I:C0024203
dissection	I:C0024203
and	O
only	O
one	O
to	O
mastectomy	O
with	O
axillary	O
nodal	I:C0024203
dissection	I:C0024203
.	O

Four	O
patients	O
underwent	O
quadrantectomy	O
and	O
in	O
two	O
cases	O
axillary	O
nodal	I:C0024203
dissection	I:C0024203
and	O
only	O
one	O
to	O
mastectomy	B:C0024881
with	O
axillary	O
nodal	I:C0024203
dissection	I:C0024203
.	O

Four	O
patients	O
underwent	O
quadrantectomy	O
and	O
in	O
two	O
cases	O
axillary	O
nodal	I:C0024203
dissection	I:C0024203
and	O
only	O
one	O
to	O
mastectomy	O
with	O
axillary	B:C0024203
nodal	I:C0024203
dissection	I:C0024203
.	O

Tumor	B:C0475440
size	I:C0475440
was	O
from	O
T1	O
to	O
T2	O
with	O
N0	O
to	O
N1	O
,	O
according	O
TNM	O
classification	I:C0809869
.	O

Tumor	O
size	I:C0475440
was	O
from	O
T1	B:C0475372
to	O
T2	O
with	O
N0	O
to	O
N1	O
,	O
according	O
TNM	O
classification	I:C0809869
.	O

Tumor	O
size	I:C0475440
was	O
from	O
T1	O
to	O
T2	B:C0475373
with	O
N0	O
to	O
N1	O
,	O
according	O
TNM	O
classification	I:C0809869
.	O

Tumor	O
size	I:C0475440
was	O
from	O
T1	O
to	O
T2	O
with	O
N0	B:C0441959
to	O
N1	O
,	O
according	O
TNM	O
classification	I:C0809869
.	O

Tumor	O
size	I:C0475440
was	O
from	O
T1	O
to	O
T2	O
with	O
N0	O
to	O
N1	B:C0441962
,	O
according	O
TNM	O
classification	I:C0809869
.	O

Tumor	O
size	I:C0475440
was	O
from	O
T1	O
to	O
T2	O
with	O
N0	O
to	O
N1	O
,	O
according	O
TNM	B:C0809869
classification	I:C0809869
.	O

Pathological	B:C0444061
specimens	I:C0444061
were	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
and	O
an	O
immunohistochemical	O
panel	O
of	O
antibodies	O
(	O
Neuron	O
-	I:C0003320
specific	I:C0003320
enolase	I:C0003320
,	O
Chromogranin	O
,	O
Synaptophysin	O
,	O
Estrogen	O
and	O
Progesterone	O
receptors	O
,	O
c-erb	O
and	O
Ki-67	O
)	O
.	O

Pathological	O
specimens	I:C0444061
were	O
stained	O
with	O
hematoxylin	B:C0018964
and	O
eosin	O
and	O
an	O
immunohistochemical	O
panel	O
of	O
antibodies	O
(	O
Neuron	O
-	I:C0003320
specific	I:C0003320
enolase	I:C0003320
,	O
Chromogranin	O
,	O
Synaptophysin	O
,	O
Estrogen	O
and	O
Progesterone	O
receptors	O
,	O
c-erb	O
and	O
Ki-67	O
)	O
.	O

Pathological	O
specimens	I:C0444061
were	O
stained	O
with	O
hematoxylin	O
and	O
eosin	B:C0021212
and	O
an	O
immunohistochemical	O
panel	O
of	O
antibodies	O
(	O
Neuron	O
-	I:C0003320
specific	I:C0003320
enolase	I:C0003320
,	O
Chromogranin	O
,	O
Synaptophysin	O
,	O
Estrogen	O
and	O
Progesterone	O
receptors	O
,	O
c-erb	O
and	O
Ki-67	O
)	O
.	O

Pathological	O
specimens	I:C0444061
were	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
and	O
an	O
immunohistochemical	O
panel	O
of	O
antibodies	B:C0813154
(	O
Neuron	O
-	I:C0003320
specific	I:C0003320
enolase	I:C0003320
,	O
Chromogranin	O
,	O
Synaptophysin	O
,	O
Estrogen	O
and	O
Progesterone	O
receptors	O
,	O
c-erb	O
and	O
Ki-67	O
)	O
.	O

Pathological	O
specimens	I:C0444061
were	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
and	O
an	O
immunohistochemical	O
panel	O
of	O
antibodies	O
(	O
Neuron	B:C0003320
-	I:C0003320
specific	I:C0003320
enolase	I:C0003320
,	O
Chromogranin	O
,	O
Synaptophysin	O
,	O
Estrogen	O
and	O
Progesterone	O
receptors	O
,	O
c-erb	O
and	O
Ki-67	O
)	O
.	O

Pathological	O
specimens	I:C0444061
were	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
and	O
an	O
immunohistochemical	O
panel	O
of	O
antibodies	O
(	O
Neuron	O
-	I:C0003320
specific	I:C0003320
enolase	I:C0003320
,	O
Chromogranin	B:C0486578
,	O
Synaptophysin	O
,	O
Estrogen	O
and	O
Progesterone	O
receptors	O
,	O
c-erb	O
and	O
Ki-67	O
)	O
.	O

Pathological	O
specimens	I:C0444061
were	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
and	O
an	O
immunohistochemical	O
panel	O
of	O
antibodies	O
(	O
Neuron	O
-	I:C0003320
specific	I:C0003320
enolase	I:C0003320
,	O
Chromogranin	O
,	O
Synaptophysin	B:C0487636
,	O
Estrogen	O
and	O
Progesterone	O
receptors	O
,	O
c-erb	O
and	O
Ki-67	O
)	O
.	O

Pathological	O
specimens	I:C0444061
were	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
and	O
an	O
immunohistochemical	O
panel	O
of	O
antibodies	O
(	O
Neuron	O
-	I:C0003320
specific	I:C0003320
enolase	I:C0003320
,	O
Chromogranin	O
,	O
Synaptophysin	O
,	O
Estrogen	O
and	O
Progesterone	O
receptors	O
,	O
c-erb	B:C0003320
and	O
Ki-67	O
)	O
.	O

Pathological	O
specimens	I:C0444061
were	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
and	O
an	O
immunohistochemical	O
panel	O
of	O
antibodies	O
(	O
Neuron	O
-	I:C0003320
specific	I:C0003320
enolase	I:C0003320
,	O
Chromogranin	O
,	O
Synaptophysin	O
,	O
Estrogen	O
and	O
Progesterone	O
receptors	O
,	O
c-erb	O
and	O
Ki-67	B:C0208804
)	O
.	O

All	O
cases	O
showed	O
markers	O
positivity	O
to	O
Neuron	B:C0003320
-	I:C0003320
specific	I:C0003320
enolase	I:C0003320
,	O
Chromogranin	O
,	O
Synaptophysin	O
and	O
Estrogen	O
and	O
Progesterone	O
receptors	O
were	O
found	O
.	O

All	O
cases	O
showed	O
markers	O
positivity	O
to	O
Neuron	O
-	I:C0003320
specific	I:C0003320
enolase	I:C0003320
,	O
Chromogranin	B:C0486578
,	O
Synaptophysin	O
and	O
Estrogen	O
and	O
Progesterone	O
receptors	O
were	O
found	O
.	O

All	O
cases	O
showed	O
markers	O
positivity	O
to	O
Neuron	O
-	I:C0003320
specific	I:C0003320
enolase	I:C0003320
,	O
Chromogranin	O
,	O
Synaptophysin	B:C0487636
and	O
Estrogen	O
and	O
Progesterone	O
receptors	O
were	O
found	O
.	O

Ki-67	B:C0208804
was	O
higher	O
than	O
40	O
%	O
in	O
four	O
patients	O
.	O

Adjuvant	B:C0085533
chemotherapy	I:C0085533
was	O
administrated	O
in	O
patients	O
with	O
Ki-67	O
>	O
10	O
%	O
;	O
every	O
patients	O
were	O
treated	O
with	O
radiotherapy	O
and	O
with	O
hormonal	O
therapy	I:C0279025
too	O
.	O

Adjuvant	O
chemotherapy	I:C0085533
was	O
administrated	B:C1533734
in	O
patients	O
with	O
Ki-67	O
>	O
10	O
%	O
;	O
every	O
patients	O
were	O
treated	O
with	O
radiotherapy	O
and	O
with	O
hormonal	O
therapy	I:C0279025
too	O
.	O

Adjuvant	O
chemotherapy	I:C0085533
was	O
administrated	O
in	O
patients	O
with	O
Ki-67	B:C0208804
>	O
10	O
%	O
;	O
every	O
patients	O
were	O
treated	O
with	O
radiotherapy	O
and	O
with	O
hormonal	O
therapy	I:C0279025
too	O
.	O

Adjuvant	O
chemotherapy	I:C0085533
was	O
administrated	O
in	O
patients	O
with	O
Ki-67	O
>	O
10	O
%	O
;	O
every	O
patients	O
were	O
treated	O
with	O
radiotherapy	B:C1522449
and	O
with	O
hormonal	O
therapy	I:C0279025
too	O
.	O

Adjuvant	O
chemotherapy	I:C0085533
was	O
administrated	O
in	O
patients	O
with	O
Ki-67	O
>	O
10	O
%	O
;	O
every	O
patients	O
were	O
treated	O
with	O
radiotherapy	O
and	O
with	O
hormonal	B:C0279025
therapy	I:C0279025
too	O
.	O

Although	O
Neuroendocrine	B:C3544078
breast	I:C3544078
tumor	I:C3544078
is	O
considered	O
a	O
distinct	O
entity	O
,	O
the	O
best	O
treatment	O
seems	O
to	O
be	O
correlate	O
to	O
the	O
size	O
of	I:C0475440
tumor	I:C0475440
and	O
to	O
the	O
lymph	O
node	I:C0024204
status	O
and	O
to	O
Ki-67	O
index	O
like	O
the	O
common	O
breast	O
cancer	I:C0678222
.	O

Although	O
Neuroendocrine	O
breast	I:C3544078
tumor	I:C3544078
is	O
considered	O
a	O
distinct	O
entity	O
,	O
the	O
best	O
treatment	B:C0087111
seems	O
to	O
be	O
correlate	O
to	O
the	O
size	O
of	I:C0475440
tumor	I:C0475440
and	O
to	O
the	O
lymph	O
node	I:C0024204
status	O
and	O
to	O
Ki-67	O
index	O
like	O
the	O
common	O
breast	O
cancer	I:C0678222
.	O

Although	O
Neuroendocrine	O
breast	I:C3544078
tumor	I:C3544078
is	O
considered	O
a	O
distinct	O
entity	O
,	O
the	O
best	O
treatment	O
seems	O
to	O
be	O
correlate	O
to	O
the	O
size	B:C0475440
of	I:C0475440
tumor	I:C0475440
and	O
to	O
the	O
lymph	O
node	I:C0024204
status	O
and	O
to	O
Ki-67	O
index	O
like	O
the	O
common	O
breast	O
cancer	I:C0678222
.	O

Although	O
Neuroendocrine	O
breast	I:C3544078
tumor	I:C3544078
is	O
considered	O
a	O
distinct	O
entity	O
,	O
the	O
best	O
treatment	O
seems	O
to	O
be	O
correlate	O
to	O
the	O
size	O
of	I:C0475440
tumor	I:C0475440
and	O
to	O
the	O
lymph	B:C0024204
node	I:C0024204
status	O
and	O
to	O
Ki-67	O
index	O
like	O
the	O
common	O
breast	O
cancer	I:C0678222
.	O

Although	O
Neuroendocrine	O
breast	I:C3544078
tumor	I:C3544078
is	O
considered	O
a	O
distinct	O
entity	O
,	O
the	O
best	O
treatment	O
seems	O
to	O
be	O
correlate	O
to	O
the	O
size	O
of	I:C0475440
tumor	I:C0475440
and	O
to	O
the	O
lymph	O
node	I:C0024204
status	O
and	O
to	O
Ki-67	B:C0208804
index	O
like	O
the	O
common	O
breast	O
cancer	I:C0678222
.	O

Although	O
Neuroendocrine	O
breast	I:C3544078
tumor	I:C3544078
is	O
considered	O
a	O
distinct	O
entity	O
,	O
the	O
best	O
treatment	O
seems	O
to	O
be	O
correlate	O
to	O
the	O
size	O
of	I:C0475440
tumor	I:C0475440
and	O
to	O
the	O
lymph	O
node	I:C0024204
status	O
and	O
to	O
Ki-67	O
index	B:C0600653
like	O
the	O
common	O
breast	O
cancer	I:C0678222
.	O

Although	O
Neuroendocrine	O
breast	I:C3544078
tumor	I:C3544078
is	O
considered	O
a	O
distinct	O
entity	O
,	O
the	O
best	O
treatment	O
seems	O
to	O
be	O
correlate	O
to	O
the	O
size	O
of	I:C0475440
tumor	I:C0475440
and	O
to	O
the	O
lymph	O
node	I:C0024204
status	O
and	O
to	O
Ki-67	O
index	O
like	O
the	O
common	O
breast	B:C0678222
cancer	I:C0678222
.	O

Diagnosis	B:C0011900
,	O
Neuroendocrine	O
breast	I:C0206695
carcinoma	I:C0206695
.	O

Diagnosis	O
,	O
Neuroendocrine	B:C0206695
breast	I:C0206695
carcinoma	I:C0206695
.	O

